Outcomes in COVID-19 adintrevimab studies
Outcomes in adintrevimab studies. mAb use may create new variants that spread globally
Focosi , Leducq , and may be associated with prolonged viral loads, clinical deterioration, and immune escape
Choudhary , Günther , Leducq .
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] death 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] death 0/240 1/241 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 studies c19 earlyApril 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Effect extraction pre-specified (most serious outcome) Favors adintrevimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] 0/240 1/241 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 mortality results c19 earlyApril 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Favors adintrevimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ EVADE PrEP Ison (DB RCT) 84% 0.16 [0.02-1.34] hosp. 1/752 6/728 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 80% 0.20 [0.01-4.15] hosp. 0/175 2/176 Tau2 = 0.00, I2 = 0.0%, p = 0.047 Prophylaxis 83% 0.17 [0.03-0.98] 1/927 8/904 83% lower risk All studies 83% 0.17 [0.03-0.98] 1/927 8/904 83% lower risk 2 adintrevimab COVID-19 hospitalization results c19 earlyApril 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.047 Favors adintrevimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] death 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] death 0/240 1/241 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 serious outcomes c19 earlyApril 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Effect extraction pre-specified (most serious outcome) Favors adintrevimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ EVADE PrEP Ison (DB RCT) 70% 0.30 [0.16-0.56] symp. case 12/752 39/728 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 75% 0.25 [0.07-0.88] symp. case 3/175 12/176 Tau2 = 0.00, I2 = 0.0%, p < 0.0001 Prophylaxis 71% 0.29 [0.16-0.51] 15/927 51/904 71% lower risk All studies 71% 0.29 [0.16-0.51] 15/927 51/904 71% lower risk 2 adintrevimab COVID-19 case results c19 earlyApril 2024 Tau2 = 0.00, I2 = 0.0%, p < 0.0001 Favors adintrevimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] death 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] death 0/240 1/241 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 Randomized Controlled Trials c19 earlyApril 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Effect extraction pre-specified (most serious outcome) Favors adintrevimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] 0/240 1/241 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 RCT mortality results c19 earlyApril 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Favors adintrevimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] death 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] death 0/240 1/241 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 peer reviewed studies c19 earlyApril 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.48 Effect extraction pre-specified (most serious outcome) Favors adintrevimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] death 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PrEP Ison (DB RCT) 50% 0.50 [0.13-1.99] death 3/1,001 6/1,001 EVADE PrEP Ison (DB RCT) 84% 0.16 [0.02-1.34] death 1/752 6/728 EVADE PrEP Ison (DB RCT) 84% 0.16 [0.02-1.34] hosp. 1/752 6/728 EVADE PrEP Ison (DB RCT) 70% 0.30 [0.16-0.56] symp. case 12/752 39/728 EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] death 0/240 1/241 EVADE PEP Ison (DB RCT) 80% 0.20 [0.01-4.15] death 0/240 2/241 EVADE PEP Ison (DB RCT) 80% 0.20 [0.01-4.15] hosp. 0/175 2/176 EVADE PEP Ison (DB RCT) 75% 0.25 [0.07-0.88] symp. case 3/175 12/176 Adintrevimab COVID-19 outcomes c19 earlyApril 2024 Favors adintrevimab Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
